<DOC>
	<DOCNO>NCT00019396</DOCNO>
	<brief_summary>RATIONALE : The drug flt3L may stimulate person 's immune system help kill tumor cell . Vaccines make melanoma cell may make body build immune response kill tumor cell . PURPOSE : Phase II trial study effectiveness flt3L without vaccine therapy treat patient metastatic melanoma renal cell cancer .</brief_summary>
	<brief_title>flt3L With Without Vaccine Therapy Treating Patients With Metastatic Melanoma Renal Cell Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate immunologic biologic activity flt3 ligand ( Flt3L ) alone patient metastatic renal cell cancer HLA-A2.1 negative melanoma . II . Evaluate immunologic biologic activity Flt3L alone combination melanoma peptide immunization ( MART-1 , gp100:209-217 , gp100:280-288 , tyrosinase ) patient metastatic , HLA-A2.1 positive melanoma . PROTOCOL OUTLINE : Patients assign 1 3 treatment group : Group 1 ( renal cell cancer ) : Patients receive Flt3 ligand ( Flt3L ) subcutaneously ( SQ ) alone day 1-14 . Group 2 ( HLA-A2.1 negative melanoma ) : Patients receive Flt3L SQ alone day 1-14 . Group 3 ( HLA-A2.1 positive melanoma ) : Patients may receive either Flt3L SQ alone day 1-14 combination melanoma peptide immunization . Patients may receive melanoma peptide immunization comprise MART-1 immunodominant peptide , gp100:209-217 , gp100:280-288 , tyrosinase peptide emulsify Montanide ISA-51 SQ day 12 Flt3L administration . Treatment repeat every 4 week 2 course . Patients response minor response may receive 2 additional course . Patients disease progression 1 course remove study . PROJECTED ACCRUAL : Approximately 54-96 patient ( 18-32 per treatment group ) accrue study within 16 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Flt3 ligand protein</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Histologically proven metastatic melanoma renal cell cancer Patients receive melanoma peptide immunization must HLAA2.1 positive Measurable disease Prior/Concurrent Therapy Biologic therapy : At least 1 month since prior biologic therapy Chemotherapy : At least 1 month since prior chemotherapy Endocrine therapy : No concurrent systemic steroid therapy At least 1 month since prior steroid therapy Radiotherapy : At least 1 month since prior radiotherapy Surgery : Prior surgery allow Other : Greater 1 month since prior therapy Patient Characteristics Age : Not specify Performance Status : ECOG 01 Life Expectancy : Greater 3 month Hematopoietic : WBC least 3,000/mm3 Platelet count least 90,000/mm3 No coagulation disorder Hepatic : Bilirubin great 1.6 mg/dL AST ALT less 2 time normal Renal : Creatinine great 2 mg/dL Cardiovascular : No major cardiovascular disease Pulmonary : No major pulmonary disease Other : Not pregnant nursing Negative pregnancy test HIV negative Hepatitis B surface antigen negative No allergic reaction Montanide ISA51 No active systemic infection No prior autoimmune disorder</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>adult solid tumor</keyword>
	<keyword>body system/site cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>kidney tumor</keyword>
	<keyword>kidney/urinary cancer</keyword>
	<keyword>melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>renal cell cancer</keyword>
	<keyword>skin tumor</keyword>
	<keyword>solid tumor</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>stage , melanoma</keyword>
	<keyword>stage , renal cell cancer</keyword>
</DOC>